179 related articles for article (PubMed ID: 33844864)
21. Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
Plesner T; Arkenau HT; Gay F; Minnema MC; Boccadoro M; Moreau P; Cavenagh J; Perrot A; Laubach JP; Krejcik J; Ahmadi T; de Boer C; Chen D; Chiu C; Schecter JM; Richardson PG
Br J Haematol; 2019 Aug; 186(3):e35-e39. PubMed ID: 30931524
[No Abstract] [Full Text] [Related]
22. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
Milani P; Fazio F; Basset M; Berno T; Larocca A; Foli A; Riva M; Benigna F; Oliva S; Nuvolone M; Rodigari L; Petrucci MT; Merlini G; Palladini G
Am J Hematol; 2020 Aug; 95(8):900-905. PubMed ID: 32282971
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Hegenbart U; Bochtler T; Benner A; Becker N; Kimmich C; Kristen AV; Beimler J; Hund E; Zorn M; Freiberger A; Gawlik M; Goldschmidt H; Hose D; Jauch A; Ho AD; Schönland SO
Haematologica; 2017 Aug; 102(8):1424-1431. PubMed ID: 28522573
[TBL] [Abstract][Full Text] [Related]
25. Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone.
Sato S; Kambe E; Tamai Y
Intern Med; 2019 Mar; 58(6):843-847. PubMed ID: 30449801
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
Denman J; Manavi K; Cook M
Int J STD AIDS; 2017 Sep; 28(10):1045-1047. PubMed ID: 28632471
[TBL] [Abstract][Full Text] [Related]
27. Daratumumab proves safe and highly effective in AL amyloidosis.
Khouri J; Kin A; Thapa B; Reu FJ; Bumma N; Samaras CJ; Liu HD; Karam MA; Reed J; Mathur S; Faiman BM; Devries G; Zonder J; Valent J
Br J Haematol; 2019 Apr; 185(2):342-344. PubMed ID: 29938774
[No Abstract] [Full Text] [Related]
28. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.
Leung N; Thomé SD; Dispenzieri A
Haematologica; 2018 Mar; 103(3):e135-e137. PubMed ID: 29351984
[No Abstract] [Full Text] [Related]
29. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.
Sher T; Fenton B; Akhtar A; Gertz MA
Blood; 2016 Oct; 128(15):1987-1989. PubMed ID: 27543437
[No Abstract] [Full Text] [Related]
30. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
[TBL] [Abstract][Full Text] [Related]
31. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
32. Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms.
Xingguang Lee L; Zhou P; Varga C; Fogaren T; Ho K; Ma X; Warner M; Toskic D; Kugelmass A; Comenzo RL
Amyloid; 2019 Jun; 26(2):101-102. PubMed ID: 31119957
[No Abstract] [Full Text] [Related]
33. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
[TBL] [Abstract][Full Text] [Related]
34. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab.
Szalat RE; Gustine J; Sloan JM; Edwards CV; Sanchorawala V
Am J Hematol; 2022 Jan; 97(1):79-89. PubMed ID: 34739735
[TBL] [Abstract][Full Text] [Related]
36. [Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy].
Nakamura A; Yamaguchi T; Ito R; Kawakami K
Rinsho Ketsueki; 2020; 61(11):1600-1604. PubMed ID: 33298653
[TBL] [Abstract][Full Text] [Related]
37. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
38. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.
Lentzsch S; Lagos GG; Comenzo RL; Zonder JA; Osman K; Pan S; Bhutani D; Pregja S; Sanchorawala V; Landau H
J Clin Oncol; 2020 May; 38(13):1455-1462. PubMed ID: 32083996
[TBL] [Abstract][Full Text] [Related]
39. The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Lee H; Tay J; Duggan P; McCulloch S; Neri P; Bahlis NJ; Jimenez-Zepeda VH
Eur J Haematol; 2021 Mar; 106(3):340-345. PubMed ID: 33197297
[TBL] [Abstract][Full Text] [Related]
40. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
